The Institute For Cancer Research
CAGE Code: 1RAF4
NCAGE Code: 1RAF4
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 064367329
Summary
The Institute For Cancer Research is an Active Commercial Supplier with the Cage Code 1RAF4 and is tracked by Dun & Bradstreet under DUNS Number 064367329..
Address
333 Cottman Ave
Philadelphia PA 19111-2434
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Faith Assembly Of God Of Frankford Dalonzo-Lancaster Inc Central National-Gottesman Warren Intl Inc Howard Refrigerator Co Inc Silver Lake Foods Inc Industrial Oil Services Inc Center For Applied Research, Inc Boyer Earl G Jr Stelwagon Mfg Co Angelo Colonno Ge Energy Rentals General Electric Co Housewares And General Electric Co Appliance And Alex Products Guilbert Inc Key Chemicals Inc American Transformer Co Auto Engineering And Machine Co Neo-Quest Chemical Co
Frequently Asked Questions (FAQ) for CAGE 1RAF4
- What is CAGE Code 1RAF4?
- 1RAF4 is the unique identifier used by NATO Organizations to reference the physical entity known as The Institute For Cancer Research located at 333 Cottman Ave, Philadelphia PA 19111-2434, United States.
- Who is CAGE Code 1RAF4?
- 1RAF4 refers to The Institute For Cancer Research located at 333 Cottman Ave, Philadelphia PA 19111-2434, United States.
- Where is CAGE Code 1RAF4 Located?
- CAGE Code 1RAF4 is located in Philadelphia, PA, USA.
Contracting History for CAGE 1RAF4 Most Recent 25 Records
- 75N91023F00001
- Colorectal Cancer (Crc) Prevention By Urolithin A In Rodent Crc Models
- 7 Jul 2023
- Colorectal Cancer (Crc) Prevention By Urolithin A In Rodent Crc Models
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,038,958.00
- Department Of Health And Human Services (Hhs)
- 75N91023F00003
- Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Biomarkers Task Order Title: Sulforaphane For The Prevention Of Malignant Mesothelioma
- 1 May 2023
- Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Biomarkers Task Order Title: Sulforaphane For The Prevention Of Malignant Mesothelioma
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,199,274.00
- Department Of Health And Human Services (Hhs)
- 75N91022F00003
- Task Order Title: Microbial Metabolite Mimicry, A Nano-Drug For Colon Cancer Prevention Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomakers
- 15 Sep 2022
- Task Order Title: Microbial Metabolite Mimicry, A Nano-Drug For Colon Cancer Prevention Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomakers
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $702,469.00
- Department Of Health And Human Services (Hhs)
- 75N91022F00001
- Base Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomakers Task Order Title: Vaccines Against Fusobacterium For Fap-And Lynch Syndrome-Associated Colorectal Cancer Immunoprevention
- 6 Nov 2023
- Base Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomakers Task Order Title: Vaccines Against Fusobacterium For Fap-And Lynch Syndrome-Associated Colorectal Cancer Immunoprevention
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,535,536.00
- Department Of Health And Human Services (Hhs)
- 75N91022F00001
- Base Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomakers Task Order Title: Vaccines Against Fusobacterium For Fap-And Lynch Syndrome-Associated Colorectal Cancer Immunoprevention
- 13 Jun 2022
- Base Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomakers Task Order Title: Vaccines Against Fusobacterium For Fap-And Lynch Syndrome-Associated Colorectal Cancer Immunoprevention
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $614,163.00
- Department Of Health And Human Services (Hhs)
- 75N91022F00002
- Task Order Title: Next Generation Gp130/Il-6/Stat3 Inhibitors For The Prevention Of Colitis-Associated Colorectal Cancer
- 17 May 2022
- Task Order Title: Next Generation Gp130/Il-6/Stat3 Inhibitors For The Prevention Of Colitis-Associated Colorectal Cancer
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,235,400.00
- Department Of Health And Human Services (Hhs)
- 75N91022F00002
- Base Contract Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers Task Order Title: Next Generation Gp130/Il-6/Stat3 Inhibitors For The Prevention Of Colitis-Associated Colorectal Cancer
- 30 Jun 2022
- Base Contract Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers Task Order Title: Next Generation Gp130/Il-6/Stat3 Inhibitors For The Prevention Of Colitis-Associated Colorectal Cancer
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,235,400.00
- Department Of Health And Human Services (Hhs)
- 75N91022F00002
- Base Contract Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers Task Order Title: Next Generation Gp130/Il-6/Stat3 Inhibitors For The Prevention Of Colitis-Associated Colorectal Cancer
- 21 Aug 2023
- Base Contract Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers Task Order Title: Next Generation Gp130/Il-6/Stat3 Inhibitors For The Prevention Of Colitis-Associated Colorectal Cancer
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $1,235,400.00
- Department Of Health And Human Services (Hhs)
- 75N91020F00001
- Base Contract Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Biomarkers Task Order: Preventing Lung Cancer By Targeting Activated Stat3
- 22 Aug 2022
- Base Contract Title: Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Biomarkers Task Order: Preventing Lung Cancer By Targeting Activated Stat3
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $779,932.00
- Department Of Health And Human Services (Hhs)
- 75N91020F00001
- Task Order: Preventing Lung Cancer By Targeting Activated Stat3
- 9 Dec 2021
- Task Order: Preventing Lung Cancer By Targeting Activated Stat3
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $779,932.00
- Department Of Health And Human Services (Hhs)
- 75N91020F00001
- Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers To Title: Preventing Lung Cancer By Targeting Activated Stat3
- 12 Jan 2023
- Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers To Title: Preventing Lung Cancer By Targeting Activated Stat3
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $779,932.00
- Department Of Health And Human Services (Hhs)
- 75N91020F00001
- Task Order: Preventing Lung Cancer By Targeting Activated Stat3
- 17 Sep 2020
- Task Order: Preventing Lung Cancer By Targeting Activated Stat3
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $779,932.00
- Department Of Health And Human Services (Hhs)
- 75N91019D00022
- Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomakers (Pop: 01/25/2019 -01/24/2024
- 24 Jan 2019
- Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomakers (Pop: 01/25/2019 -01/24/2024
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $0.00
- Department Of Health And Human Services (Hhs)
- 75N91019D00022
- Prevent Preclinical Efficacy And Intermediate Endpoint Biomarkers
- 22 Nov 2022
- Prevent Preclinical Efficacy And Intermediate Endpoint Biomarkers
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $0.00
- Department Of Health And Human Services (Hhs)
- 75N91019D00022
- Eo14042 - Prevent Preclinical Efficacy And Intermediate Endpoint Biomarkers
- 16 Nov 2021
- Eo14042 - Prevent Preclinical Efficacy And Intermediate Endpoint Biomarkers
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $0.00
- Department Of Health And Human Services (Hhs)
- 75N91018F00003
- Eo14042 - Prevent: To Title: Novel Non-Cox Inhibitory Sulindac Derivative For Colorectal Cancer Chemoprevention With Selective Pde-10 And Wnt/B-Catenin Inhibitory Activity
- 22 Nov 2021
- Eo14042 - Prevent: To Title: Novel Non-Cox Inhibitory Sulindac Derivative For Colorectal Cancer Chemoprevention With Selective Pde-10 And Wnt/B-Catenin Inhibitory Activity
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $890,103.00
- Department Of Health And Human Services (Hhs)
- HHSN26100002
- Prevent: To Title: Targeting The Il Signal Pathway As Chemoprevention Therapy For High Risk Malignant Mesothelioma Populations
- 16 Feb 2022
- Prevent: To Title: Targeting The Il Signal Pathway As Chemoprevention Therapy For High Risk Malignant Mesothelioma Populations
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $989,435.00
- Department Of Health And Human Services (Hhs)
- 75N91019D00022
- Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomakers (Pop: 01/25/2019 -01/24/2024
- 28 May 2019
- Prevent Preclinical Drug Development Program: Preclinical Efficacy And Intermediate Endpoint Biomakers (Pop: 01/25/2019 -01/24/2024
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $0.00
- Department Of Health And Human Services (Hhs)
- 75N91018F00003
- Preclinical Prevent Cancer Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers To Title: Novel Non-Cox Inhibitory Sulindac Derivative For Colorectal Cancer Chemoprevention With Selective Pde-10 And Wnt/B-Catenin Inhibitory Activity
- 6 Jun 2023
- Preclinical Prevent Cancer Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers To Title: Novel Non-Cox Inhibitory Sulindac Derivative For Colorectal Cancer Chemoprevention With Selective Pde-10 And Wnt/B-Catenin Inhibitory Activity
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $884,185.34
- Department Of Health And Human Services (Hhs)
- 75N91019D00022
- Prevent Preclinical Efficacy And Intermediate Endpoint Biomarkers
- 28 Mar 2023
- Prevent Preclinical Efficacy And Intermediate Endpoint Biomarkers
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $0.00
- Department Of Health And Human Services (Hhs)
- 75N91020P00955
- Institute For Cancer Research:1186568 [20-036787] Etiology Of Lung Cancer In Never Smokers And Special Exposure Cohorts
- 10 Sep 2021
- Institute For Cancer Research:1186568 [20-036787] Etiology Of Lung Cancer In Never Smokers And Special Exposure Cohorts
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $24,900.00
- Department Of Health And Human Services (Hhs)
- HHSN26100002
- Prevent: To Title: Targeting The Il Signal Pathway As Chemoprevention Therapy For High Risk Malignant Mesothelioma Populations
- 13 Jun 2022
- Prevent: To Title: Targeting The Il Signal Pathway As Chemoprevention Therapy For High Risk Malignant Mesothelioma Populations
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $988,252.00
- Department Of Health And Human Services (Hhs)
- HHSN26100002
- Targeting The Il Signal Pathway As Chemoprevention Therapy For High Risk Malignant Mesothelioma Populations
- 2 Sep 2021
- Targeting The Il Signal Pathway As Chemoprevention Therapy For High Risk Malignant Mesothelioma Populations
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $989,435.00
- Department Of Health And Human Services (Hhs)
- 75N91019D00022
- Preclinical Efficacy And Intermediate Endpoint Biomarkers
- 27 Aug 2021
- Preclinical Efficacy And Intermediate Endpoint Biomarkers
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $0.00
- Department Of Health And Human Services (Hhs)
- 75N91018F00003
- Preclinical Prevent Cancer Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers To Title: Novel Non-Cox Inhibitory Sulindac Derivative For Colorectal Cancer Chemoprevention With Selective Pde-10 And Wnt/B-Catenin Inhibitory Activity
- 22 Jun 2023
- Preclinical Prevent Cancer Program: Preclinical Efficacy And Intermediate Endpoint Biomarkers To Title: Novel Non-Cox Inhibitory Sulindac Derivative For Colorectal Cancer Chemoprevention With Selective Pde-10 And Wnt/B-Catenin Inhibitory Activity
- Nih Nci
- Department Of Health And Human Services (Hhs)
- $884,185.34
- Department Of Health And Human Services (Hhs)